Himmelfarb Health Sciences Library, The George Washington University

Health Sciences Research Commons
Pediatrics Faculty Publications

Pediatrics

10-2013

Incidence of methicillin-resistant staphylococcus
aureus infection in a children's hospital in the
Washington metropolitan area of the United States,
2003-2010
Xiaoyan Song
George Washington University

Joanthan Cogen
George Washington University

Nalini Singh
George Washington University

Follow this and additional works at: http://hsrc.himmelfarb.gwu.edu/smhs_peds_facpubs
Part of the Pediatrics Commons
Recommended Citation
Song, X., Cogen, J., & Singh, N. (2013). Incidence of methicillin-resistant staphylococcus aureus infection in a children's hospital in
the washington metropolitan area of the united states, 2003-2010. Emerging Microbes and Infections, 2:e69.

This Journal Article is brought to you for free and open access by the Pediatrics at Health Sciences Research Commons. It has been accepted for
inclusion in Pediatrics Faculty Publications by an authorized administrator of Health Sciences Research Commons. For more information, please
contact hsrc@gwu.edu.

Emerging Microbes and Infections (2013) 2, e69; doi:10.1038/emi.2013.69
ß 2013 SSCC. All rights reserved 2222-1751/13
www.nature.com/emi

ORIGINAL ARTICLE

Incidence of methicillin-resistant Staphylococcus aureus
infection in a children’s hospital in the Washington
metropolitan area of the United States, 2003 – 2010
Xiaoyan Song1,2, Jonathan Cogen3 and Nalini Singh1,2
Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a major public health threat. In this retrospective cohort study, we
included patients with laboratory-confirmed MRSA infections treated at Children’s National Medical Center in Washington, District of
Columbia between July 2003 and December 2010. The secular trends in the incidence rates of skin/soft tissue and invasive MRSA
infections were assessed. Molecular analyses were performed on a subset of patients with invasive infections whose MRSA isolates
were available for genotyping. The study identified 3750 patients with MRSA infections. The incidence of MRSA infections peaked in
2007 (incidence rate: 5.34 per 1000 patient-visits) and subsequently declined at a rate of 5% per year. By December 2010, the MRSA
incidence rate reached 3.77 per 1000 patient-visits. Seventeen (14.7%) patients with invasive MRSA infections died, and the
mortality risk significantly increased if the MRSA infections were healthcare-associated (HA) or if an isolate was resistant to
clindamycin and/or trimethoprim/sulfamethoxazole. In conclusion, this study described a descending trend in MRSA infections in
children since 2007. Although invasive MRSA infections only accounted for a small portion of the total MRSA infections, they were
associated with a high mortality risk. The prevention and control of the spread of MRSA remains a crucial and challenging task.
Emerging Microbes and Infections (2013) 2, e69; doi:10.1038/emi.2013.69; published online 9 October 2013
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INTRODUCTION
In the late 1990s, dramatic increases in the frequency of communityacquired methicillin-resistant Staphylococcus aureus (MRSA) infections
were noted among children without established risk factors for MRSA
infections (e.g., recent hospitalization, recent surgery, residence in a
long-term care facility or injection-drug use).1 Between 1996 and
1999, MRSA was linked to at least four fatal infections in pediatric
population patients.2 These incidents indicated that serious MRSA
infections could be acquired in the community and suggested the emergence of a new community strain that was different from the strain
isolated in healthcare settings.1–3 Since then, MRSA has been recognized
as a major threat to public health. In 2005 alone, the Centers for Disease
Control and Prevention estimated that 94 360 invasive MRSA infections
occurred in the United States, and these infections were associated with 18 650 deaths.4 Due to nationwide MRSA outbreaks5–11
and the increase of MRSA skin and soft tissue infections in patients
seeking emergency care,12–14 the prevention of MRSA in both community and healthcare settings has been a priority. Strategies including active screening, the use of contact precautions and decolonization
have been enforced through legislative efforts, as well as evidencebased practices. By 2009, a subsequent study conducted in the same
patient population revealed that invasive MRSA infections in the
United States had decreased, largely due to the reduction in central
line-associated bloodstream infections in healthcare settings.15
1

We recognized that the identification of the epidemiology and
infection patterns in local hospital settings remains critical as it
directly affects clinical management plans and patient outcomes.
Therefore, we conducted this study to describe the epidemiological
characteristics of patients with MRSA infections treated at a freestanding children’s hospital in the District of Columbia (DC).
MATERIALS AND METHODS
Study setting
This study was conducted at the Children’s National Medical Center
(CNMC) in Washington, DC. As the only exclusive provider of
pediatric care in the metropolitan Washington area and the only freestanding children’s hospital between Philadelphia, Pittsburgh,
Norfolk and Atlanta, the hospital serves as the regional referral center
for pediatric emergency, trauma, cancer, cardiac and critical care, as
well as neonatology, orthopedic surgery, neurology and neurosurgery.
The Children’s Hospital at CNMC features 303 inpatient beds, an
emergency department (ED) that treats an average of 70 000 patients
each year and clinics that provide primary and specialty outpatient
care for newborns up to adolescents.
Study design and patient population
This was a retrospective cohort study that included patients treated for
a MRSA infection at CNMC between July 2003 and December 2010;
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these infections were confirmed by the microbiology laboratory at
CNMC.
Skin and soft tissue infections due to Staphylococcus aureus (S. aureus) were isolated from a specimen of the selected body site, including
nail, arm, axilla, back, buttock, catheter insertion site, face, finger, foot,
leg, vesicle, neck, nose, penis, perianal area, scrotum, skin, toe, umbilicus or genital site.
An infection was classified as invasive MRSA if it was recovered
from a specimen collected at a normally sterile site, such as blood,
peritoneal fluid, cerebrospinal fluid, joint/synovial fluid, pleural fluid,
bone, pericardial fluid or from an internal body site, such as lymph
node, brain, heart, liver, spleen, vitreous fluid, kidney, pancreas or
ovary.4
Cases of invasive infection were further classified as healthcareassociated (HA) if the patients had one or more of the following risk
factors: history of hospitalization in the past year, the presence of a
percutaneous device or indwelling catheter, dialysis within the previous
year, history of MRSA infection or colonization, history of surgery
within 1 year prior to the culture date or history of residence at a
long-term care facility.14 Patients with no documented healthcare risks
or cases with positive cultures from normally sterile sites obtained at
admission or within 48 h of admission without documented HA risk
factors were considered to have community-associated MRSA (CAMRSA) infections.
Microbiology testing and genetic analysis
MRSA was detected using 5% sheep blood agar, chocolate agar and
CNA agar. If there was a specific request for a MRSA rule out, mannitol
salt agar was added to the inoculation media for the detection of
MRSA.
Genetic analysis using repetitive sequence-based PCR (DiversiLab;
bioMerieux Inc., Durham, North Carolina, USA) was performed for a
subset of cases with invasive infections if their MRSA isolates remained
viable at the time of this study. Samples for genetic analysis were first
re-cultured on a standard blood agar medium. Colonies of viable
isolates were extracted, amplified and detected via electrophoresis to
determine the specific genetic patterns. These patterns were then compared to a DNA database provided by the manufacturer and classified
as identical if a 95% or higher similarity was detected.
Data sources
Cases of MRSA infections detected at the CNMC microbiology laboratory were identified from the laboratory information system
(Sunquest Information Systems; Sunquest Information Systems,
Inc., Tuscan, Arizona, USA). The database provided patient identifiers, date of birth, specimen collection date, location and body site,
and MRSA susceptibility to a panel of antimicrobial agents.
Additional information was extracted from the medical charts for
cases with invasive infections diagnosed between January 2006 and
December 2010. This included risk factors determining the status of
HA versus CA infections, duration of intensive care if applicable,
duration of hospitalization and death at the time of discharge.
Statistical analysis
We calculated the annual incidence rate of MRSA infections per 1000
patient-encounters over a 12-month fiscal year (FY) period (July
through June of the following year). Patient-encounters were defined
as the number of patient visits in the ED and/or inpatient admissions.
Changes in the annual incidence rate were tested using Poisson
regression analysis for statistical significance. In addition, we assessed
Emerging Microbes and Infections

changes in regards to the proportion of MRSA-invasive infections
compared to the total MRSA infections detected every year.
Unadjusted logistic regression analysis was performed to identify
factors that independently predicted the risk of death in cases with
invasive infections. All analyses were performed using Stata 11.0 (Stata
Corp., College Station, Texas, USA).
This study was approved by the Institutional Review Board of
Children’s Research Institutes.
RESULTS
Secular trend in incidence rate of MRSA infections
During the study period of July 2003 through December 2010, 3750
patients that were seeking medical care at our facility had a MRSA
infection confirmed by the microbiology testing. As shown in Figure 1,
MRSA infections increased significantly from 0.93 per 1000 patientencounters in FY 2004 to a peak of 5.34 per 1000 patient-encounters in
FY 2007. Beginning in July 2007, the MRSA incidence rate steadily
declined at a rate of 5% every year (incidence rate ratio (IRR): 0.95;
95% confidence interval (CI): 0.94–0.98) and reached 3.77 per 1000
patient-encounters by December 2010.
Over half (54.6%) of these MRSA infections were skin and soft
tissue infections treated in the ED. Similar to the overall MRSA incidence rates, the skin and soft tissue infections treated in the ED rose
rapidly in FY 2004 from 0.54 to 4.95 per 1000 patient-encounters in FY
2007. Afterwards, the incidence began to decline and reached 2.56 per
1000 patient-encounters by December 2010.
Invasive infections accounted for 5.4% of the MRSA infections in
this study cohort. The incidence was the highest in FY 2006 (0.35 per
1000 patient-encounters) and declined at a rate of 19% each year (IRR:
0.81; 95% CI: 0.74–0.90).
The proportion of MRSA in all S. aureus isolated cultures remained
relatively stable. MRSA comprised an average of 57.7% of all S. aureus
isolates. Of the patients treated in the ED for a skin or soft tissue
infection caused by S. aureus, MRSA accounted for 71.8% of the isolates.
Epidemiological and clinical characteristics of patients with
invasive infections
Of the 128 patients with invasive MRSA infections during the study
period, 116 cases had complete charts for review and were included in
the analysis. Of these patients, 58 (50%) were male, and 76 (65.5%)
were African American. The majority (n581, 70%) of the patients
were children younger than five years old, including 15 neonates
who were 28 days or younger and 42 infants aged between 29 days
and one year old.
Bacteremia was the most common invasive infection (31.9%), followed by osteomyelitis (22.4%) and abscess (19.8%). Sixty-four
(55.2%) cases met the criteria for HA infections, and the remaining
52 cases were CA. Of these HA cases, two MRSA isolates were resistant
to both clindamycin and trimethoprim/sulfamethoxazole and 33
MRSA isolates were resistant to only clindamycin.
Seventeen (14.7%) patients in this cohort died. The mortality risk
increased significantly if the MRSA infections were HA (IRR: 1.63;
95% CI: 1.22–2.19) or caused by a MRSA isolate resistant to clindamycin and/or trimethoprim/sulfamethoxazole (IRR: 2.54; 95% CI:
1.69 – 3.76).
Molecular epidemiology of invasive MRSA infections
The MRSA isolates for 53 cases were available for molecular genotyping. The USA300 strain was the predominant type for both the
HA-MRSA and CA-MRSA infections and accounted for 66.0% of
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Figure 1 Incidence of methicillin-resistant Staphylococcus aureus infections in a children’s hospital in the Washington metropolitan area of the United States, 2003–
2010.
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the isolates. This was followed by the USA100 and USA200 strains
combined (15.1%) and the USA500 strain (11.3%). Eight of the 12
osteomyelitis cases, eight of the 11 pneumonia cases, and seven of the
11 abscess cases were caused by the USA300 strain (Figure 2). One
isolate of the USA300 strain developed resistance to clindamycin
but remained susceptible to trimethoprim/sulfamethoxazole. MRSA
USA100 and USA200 were mainly found in HA-MRSA pneumonias
(n52; 8%) and bacteremia (n53, 12.5%). Of the 25 strains causing
HA-MRSA infections, nine developed resistance to clindamycin but
remained susceptible to trimethoprim/sulfamethoxazole. The distribution of the strain types among the five deaths was two for the
USA100 strain, two for the USA 200 strain and one for the USA300
strain.

DISCUSSION
In this retrospective study, we described the secular trends of MRSA infections identified amongpediatric patients receiving medicalcareinourfacility
between July 2003 and December 2010. In this seven-year study, MRSA
infections reached the highest incidence rate in 2007 and then declined
steadily. The same pattern was observed among children in California16
and veterans in Atlanta17 and Maryland.18 These data seemed to suggest that
the decline of MRSA infections might have affected adults and children in a
growing number of geographic locations in the United States.
As expected,19,20 most of the MRSA cases identified in our study
were skin and soft tissue infections encountered in the ED. These
findings were similar to those reported by Gerber et al. who described
the national trend, as well as characteristics, of S. aureus infections
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Figure 2 Distribution of MRSA strain type by the infection site and source. CSF, cerebrospinal fluid.
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among patients seeking medical care in one of the 40 free-standing
children’s hospitals supplying administrative discharge data to the
Pediatric Health Information System.
Gerber’s study included patients discharged from one of the
Pediatric Health Information System hospitals between 2002 and
2007. In contrast, our study has extended the study period to 2010
and was able to demonstrate a descending trend of MRSA infections
that started in 2007. The decline of MRSA central line bloodstream
infections among patients was seen in a subset of intensive care units
participating in the National Healthcare Safety Network.21,22 Since the
publication of the population-based national studies in 2006,4,13 many
interventions, ranging from mandatory active screening in patients
admitted to medical facilities to public health education campaigns
on the prevention and control of MRSA in residential places, were
implemented.23,24 Although we could not attribute the decline in
MRSA infections observed in our study to any particular intervention,
it was plausible that communities in a metropolitan area, such as the
DC, were having increasing success in limiting the spread of MRSA.
The decline in the overall MRSA infection rate had a small impact
on the proportion of MRSA in the total number of S. aureus isolates. In
our study cohort, 70% of the S. aureus infections were MRSA infections. This proportion remained constant and was nearly double the
national MRSA prevalence that was estimated prior to the wide spread
of MRSA in communities.25 Therefore, the empirical management of
all infections when S. aureus is suspected should include treatment for
MRSA.
Despite the decline in overall incidence, MRSA remains a major
health threat to individual pediatric patients. In particular, patients
with a history of MRSA colonization are predisposed to invasive
MRSA infections, which could be life threatening and carry a 15%
crude mortality risk.
The USA300 strain was established as the predominant cause of
community-acquired infection in the United States. Although the
USA300 strain was commonly associated with skin and soft tissue
infections, the USA300 strain has caused an increasing number of
invasive infections, as previously reported.26,27 In a neonatal intensive
care unit, the USA300 strain emerged as the principal clone by 2007.28
In contrast to previous studies, we found that the USA300 strain was
not only responsible for a large proportion (up to 66%) of the overall
MRSA infections, but it was also responsible for invasive infections,
including pneumonia and osteomyelitis, in children and young adolescents.
As a single site epidemiology study, we recognize the inherent limitations, such as the lack of generalizability, in this study. Nonetheless,
this study took place in a regional referral center that serves a large
metropolitan area on the east coast of the United States. This study
was further strengthened by the inclusion of a large cohort of nearly
4000 patients with lab confirmed MRSA infections. Second, limited by
the information available for the study, we were unable to determine
the factors that contributed to the decline in MRSA incidence.
Particularly, because we only examined MRSA skin and soft tissue
infections confirmed by a positive microbiology culture, it is plausible
that an increased use of empirical management of skin infections
without culturing had contributed to the decline in MRSA incidence.
Third, limited by resources, we did not collect data on the drug susceptibility of the MRSA strains other than clindamycin and trimethoprim/sulfamethoxazole. Therefore, further studies are warranted to
provide a more comprehensive description of the drug susceptibility
patterns associated with MRSA strains and infections. Fourth, the
information on the patients with invasive infections was extracted
Emerging Microbes and Infections

from electronic medical records. Although this approach reduced
the information bias during documentation, incomplete charting
could lead to gaps in knowledge. Finally, this study was limited by a
small sample size of patients with invasive infections and a lack of
information on the patient’s underlying diseases to adequately control
for confounders.
Taken together, this retrospective observational study noted that
the incidence of MRSA infections peaked in 2007 and has since
declined. Although invasive MRSA infections only accounted for a
small portion, these infections were associated with a high mortality
rate. The prevention and control of the spread of MRSA remains a
crucial yet challenging task. Large multicenter- and population-based
studies are needed to reassess the burden of MRSA infections one
decade after its spread into communities and to determine the effectiveness of the current prevention strategies.
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